A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Conditions: Advanced Solid Tumor; Melanoma; Head and Neck Cancer; Gastric Cancer; Ovarian Carcinoma; Cervical Cancer; Endometrial Cancer; Bladder Cancer; Esophageal Cancer; Pancreatic Carcinoma; Prostate Cancer
Interventions: Drug: HER3-DXd
Sponsors: Daiichi Sankyo; Merck Sharp & Dohme LLC
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 21, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments